SMO and skin basal cell carcinoma: Three SMO antagonists were recently approved by the US FDA, Vismodegib (Erivedge®) in 2012 for BCC, Sonidegib (Odomzo®) in 2015 for BCC and Glasdegib (DaurismoTM) in 2018 for acute myeloid leukemia (AML).